A phase II trial of m-AMSA in patients with small-cell lung cancerNatale, R. B.; Cralla, R. J.; Wittes, B. E.American Journal of Clinical Oncology: January 1981 - Volume 4 - Issue 4 - p 393–396 ARTICLE: PDF Only Buy Abstract Author InformationAuthors EIGHTEEN PATIENTS with small-cell lung cancer were treated with m-AMSA in doses of 90 mg/m2 or 120 mg/m2 intravenously every 3 weeks. There were no useful therapeutic responses in the 16 patients receiving adequate trials of the drug. Myelosuppression was the only significant dose-limiting side effect of treatment m-AMSA in this dose and schedule is not sufficiently active in small-cell luug eancer to warrant further study in a heavily treated patient population. Solid Tumor and Developmental Chemotherapy Services, Department of Medicine. Memorial Sloan-Ket tering Cancer Center. New York, New York. © Lippincott-Raven Publishers.